$PYPD

PolyPid Ltd.

PolyPid develops long-acting, controlled-release medicines designed to deliver drugs locally at the site of care. Its PLEX technology uses polymer and lipid layers to encapsulate medication and release it at predetermined rates and durations. The lead product candidate, D-PLEX100, combines PLEX with doxycycline and is applied during surgery to release antibiotic at the surgical site for 30 days, with development focused on preventing surgical site infections. Other programs include a long-acting GLP-1 receptor agonist delivery platform for metabolic diseases and OncoPLEX, an intra-tumoral cancer therapy candidate. PolyPid also collaborates on drug formulation research, including with ImmunoGenesis, and has granted Advanz exclusive marketing and distribution rights for D-PLEX100 in the EEA and United Kingdom. PolyPid operates a sterile manufacturing facility in Israel and is headquartered at 18 Hasivim Street, Petach Tikva, Israel. It seeks to make money through commercialization of its medicines and licensing or collaboration arrangements involving its drug-delivery technologies.

No enriched coverage for $PYPD in the last 7 days.

No SEC Form 4 filings for $PYPD in the last 30 days.

See all $PYPD insider activity →
Med

PolyPid Ltd. (PYPD): Financial results for Q3 2026

PolyPid Ltd. (PYPD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results D-PLEX₁₀₀ NDA Under FDA Priority Review with PDUFA Goal Date of November 28, 2026; U.S. Commercial Launch Preparations Ongoing Expanding D-PLEX₁₀₀ Globally: MAA Submitted and Validated

PolyPid reports Q3 results (PYPD:NASDAQ)

PolyPid reported Q3 GAAP EPS of -$0.24, with a net loss of $5.8M, down from $7.5M a year prior. Cash reserves increased to $15.5M from $12.9M. Results may not align with estimates.

PolyPid unveils PD01B for diabetic foot infection treatment

PolyPid Ltd. (NASDAQ:PYPD) introduced PD01B, a product candidate for treating moderate to severe diabetic foot infections, using its Kynatrix delivery technology. The company plans to initiate a first-in-human study in the second half of 2027. PolyPid also expects a decision on its lead product D-PLEX₁₀₀ by November 28, 2026, with a potential U.S. launch in early 2027, subject to FDA approval.

PYPD sentiment & insider activity

Recent PYPD coverage spans regulation, financial news and earnings.

What's driving PYPD

AlphAI scores every news story that mentions PYPD with an AI model for sentiment and relevance, and aggregates insider trades from PolyPid Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $PYPD

Score
$PYPDMedEarnings

PolyPid Ltd. (PYPD): Financial results for Q3 2026

PolyPid Ltd. (PYPD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results D-PLEX₁₀₀ NDA Under FDA Priority Review with PDUFA Goal Date of November 28, 2026; U.S. Commercial Launch Preparations Ongoing Expanding D-PLEX₁₀₀ Globally: MAA Submitted and Validated

$PYPDMedAI 8/10

PolyPid unveils PD01B for diabetic foot infection treatment

PolyPid Ltd. (NASDAQ:PYPD) introduced PD01B, a product candidate for treating moderate to severe diabetic foot infections, using its Kynatrix delivery technology. The company plans to initiate a first-in-human study in the second half of 2027. PolyPid also expects a decision on its lead product D-PLEX₁₀₀ by November 28, 2026, with a potential U.S. launch in early 2027, subject to FDA approval.

$PYPDHighAI 8/10

Oppenheimer initiates PolyPid stock coverage with outperform rating

Oppenheimer initiated coverage on PolyPid (NASDAQ:PYPD) with an outperform rating and a $10.00 price target. The stock is up 47% over the past year, with a Strong Buy consensus and targets ranging from $8 to $14. PolyPid's D-PLEX100 reduced surgical site infections by 60% in a Phase 3 study and is under FDA Priority Review. The company reported a narrower Q2 2026 loss of $0.35 per share, beating expectations.

European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀

PolyPid's (PYPD) Marketing Authorization Application for D-PLEX₁₀₀, a drug to prevent post-abdominal surgery infections, has been validated by the European Medicines Agency. The application is now under formal review. The FDA is also reviewing D-PLEX₁₀₀ under Priority Review with a PDUFA goal date of November 28, 2026. The drug showed a 60% relative risk reduction in surgical site infections in a Phase 3 trial.

HighAI 8/10

PolyPid (PYPD) Q2 2026 Earnings Call Transcript

PolyPid (PYPD) reported Q2 2026 milestones: FDA accepted its NDA for D-PLEX100 with Priority Review, setting a PDUFA goal date of November 28, 2026. The company also signed a $320M+ commercialization deal with Azurity Pharmaceuticals for the U.S. and Canada, including upfront payments, milestones, and royalties. PolyPid plans to submit an MAA to the EMA in Q3 2026 and expects a U.S. launch in early 2027.

PolyPid Ltd. Q2 2026 Earnings Call Summary

PolyPid said the FDA accepted its D-PLEX100 NDA with Priority Review and no filing issues, targeting a PDUFA date of Nov. 28, 2026. It signed an exclusive U.S. and Canada commercialization deal with Azurity, including upfront and tiered royalties plus a transfer price for retained manufacturing units. PolyPid expects a U.S. launch in early 2027 and $30M in milestone payments.

Related tickers